Amrize stock closed at CHF34.14 on Thursday, roughly flat over the past week after a softer 90 day stretch. However, the fresh Q3 2026 earnings tell a more nuanced story than the price suggests. The headline is margin resilience. Net profit reached US$559m on revenue of US$3.77b, and trailing net profit margin across the past year is 10.2%, slightly higher than a year ago.
Short term traders are reacting to a cement and roofing supplier that still feels cyclical. Longer term investors are weighing that steady profitability against mixed valuation signals and a balance sheet that carries meaningful debt.
Like the profitability at Amrize but uneasy about the debt load and cyclicality? Compare that profile with our screener of companies that pair sturdy earnings with stronger balance sheets in the list of solid balance sheet and fundamentals stocks (207 results).
Q3 2026 Earnings Summary
- Revenue, Q3 2026 vs Q3 2025: US$3,771m vs US$3,675m (up 2.6%)
- Net Income, Q3 2026 vs Q3 2025: US$559m vs US$545m (up 2.6%)
- Basic EPS, Q3 2026 vs Q3 2025: US$1.03 vs US$0.99 (up 4.2%)
- Net Profit Margin, Trailing 12 Months vs Prior Year: 10.2% vs 9.8% (higher margin on a trailing basis)
Amrize grew profit despite weaker cement and roofing volumes. Ask Charlie what’s really driving Amrize’s pricing power now.
Evaluating Amrize’s Capacity and Synergy Milestones
The bullish script leans heavily on Amrize turning large projects and cost programs into structurally lower unit costs and higher margins.
"Major efficiency and capacity investments, including the Ste. Genevieve expansion, Malarkey shingles factory in Indiana, St. Constant and Exshaw cement projects and Midlothian upgrades, are set to add low cost capacity that can expand EBITDA margins as utilization rises."
Q3 results partially support that ambition. Building Materials adjusted EBITDA rose faster than its revenue, helped by pricing, quarry expansions and plant debottlenecking. Roofing tells a different story. Residential softness and higher freight and petrochemical costs dragged Building Envelope EBITDA, and management now points to 2027 for price over cost parity there.
Not everyone reads the same price the same way. → See the higher figure this Narrative lands on, and how it gets there.
Amrize Bear Case: Cost Pressures Still Biting
Bearish investors worry that Amrize loads up on capacity projects and then lives with the bill if demand or execution disappoints.
"Although the Ste. Genevieve, St. Constant, Midlothian and Exshaw capacity projects aim to improve efficiency and output, slower ramp up or weaker utilization could leave Amrize carrying higher depreciation and operating costs, which would pressure EBITDA and net margins."
Q3 shows that concern partly playing out. Building Materials adjusted EBITDA still improved, yet required heavy Q3 CapEx and pricing gains to offset softer cement and aggregates volumes. Roofing margins went the other way, with higher freight and petrochemical inputs and weaker shingles volumes cutting Building Envelope EBITDA, and recovery there now pushed into 2027.
Hunt For Quietly Mispriced Compounders
Amrize just showed how a steady margin story can still leave the share price treading water. The real opportunity is spotting companies that could be undervalued before that gap attracts fast capital.
- Company 1 - 37% below our estimate - shifts hospital equipment lines toward recurring consumables and sterile workflow services that lift mix quality.
- Company 2 - 21% below our estimate - sells software defined routers that lock in subscriptions as clients add satellite links and physical AI devices across dispersed sites.
- Company 3 - 39% below our estimate - grows fee based earnings by pushing clients toward higher rate private credit and real asset funds backed by its own co investments.
Those are three of them. See every one of the 191 undervalued companies on it →
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com